Nektar Therapeutics is Friday's top mover after declining 49.66%

Leading equity indices in the US declined as Nasdaq lost 1.69% and ended the session at 11,400. Dow Jones slipped 1.02% and closed at 32,817.

“Top Movers” are assets that recorded the highest percentage change compared to their nearest peers. Friday's most active healthcare stocks are listed below.

Bullish mood lifts Guardant Health to session high of $29.67

The cancer treatment developer closed Thursday at $25.86. Friday, it gained 11.68% and remained around $28.88. Currently, the cancer treatment developer has a market capitalization of $2.96 billion with an average daily volume of 2.19 million shares. So far this year, it has been doing worse than the Nasdaq by 0.86%.

Guardant Health released its quarterly earnings report Thursday, beating analysts estimates. The company reported earnings of -1.36 per share on revenue of $126.89 million, topping estimates of -1.4 per share on revenue of $123.93 million. Since the release of its earnings report, Guardant Health gained 4.41%.

Nektar Therapeutics lost 49.66% ahead of quarterly report today, drops another 2% in pre-market trading

Friday's session continued down the same path: early in Friday's session, Nektar Therapeutics dropped to $1.46 from $2.96 at the end of Thursday, before closing at $1.49. During the session, it lost 49.66%. Nektar Therapeutics's market cap currently stands at $280 million with an average daily trading volume of 2.46 million shares.

Nektar Therapeutics is scheduled to announce earnings results today. The consensus EPS estimate is -0.45 and the consensus revenue estimate is $22.61 million.

UroGen Pharma | Closed 71 cents (-6.83%) lower at $9.69

The biotechnology company now trading 25.3% above its 3-month low of $5.12. Currently, the urothelial and specialty cancer treatment company has a market capitalization of $223.74 million with an average daily trading volume of 117,133 shares. UroGen Pharma last reported revenue of $16 million with an EPS of $-1.13.